Open AccessAtrial Fibrillation Patients Treated With Long‐Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long‐Term Warfarin for Other Indications
Author(s) -
Bunch T. Jared,
May Heidi T.,
Bair Tami L.,
Crandall Brian G.,
Cutler Michael J.,
Day John D.,
Jacobs Victoria,
Mallender Charles,
Osborn Jeffrey S.,
Stevens Scott M.,
Weiss J. Peter,
Woller Scott C.
Publication year - 2016
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.116.003932
Subject(s) - medicine , atrial fibrillation , dementia , warfarin , hazard ratio , stroke (engine) , vascular dementia , cardiology , diabetes mellitus , heart failure , disease , confidence interval , endocrinology , mechanical engineering , engineering
Background The mechanisms behind the association of atrial fibrillation ( AF ) and dementia are unknown. We previously found a significantly increased risk of dementia in AF patients taking warfarin with a low percentage of time in therapeutic range. The purpose of this study was to determine the extent to which AF itself increases dementia risk, in addition to long‐term anticoagulation exposure. Methods and Results A total of 10 537 patients anticoagulated with warfarin (target INR 2–3), managed by the Clinical Pharmacist Anticoagulation Service with no history of dementia were included. Warfarin indication was for AF (n=4460), thromboembolism (n=5868), and mechanical heart valve(s) (n=209). Patients in the latter 2 categories were included only if they had no prior history of AF . The primary outcome was dementia. Patients with AF were older and had higher rates of hypertension, diabetes, heart failure, and stroke. AF patients experienced higher rates of total dementia (5.8% versus 1.6%, P <0.0001), Alzheimer disease (2.8% versus 0.9%, P <0.0001), and vascular dementia (1.0% versus 0.2%, P <0.0001). A propensity analysis of 6030 patients was performed to account for baseline demographics differences. Long‐term risk of dementia remained significant in AF patients compared with matched non‐ AF patients (total dementia: hazard ratio [HR]=2.42 [1.85–3.18], P <0.0001; Alzheimer: HR =2.04 [1.40–2.98], P <0.0001; senile: HR =2.46 [1.58–3.86], P <0.0001). Low percent therapeutic range compared with a higher percent therapeutic range was associated with dementia risk in both AF (26–50% versus >75%: HR =2.51, P =0.005) and non‐ AF groups (≤25% versus >75%: HR =3.92, P <0.0001). Conclusions The presence of AF significantly increases risk of dementia, including Alzheimer's disease, compared with matched patients receiving warfarin anticoagulation for other reasons. Quality of anticoagulation management remains an important risk factor for dementia in all patients.